Osmetech plc (Osmetech), a molecular diagnostics company, announces that it has signed a five-year distribution agreement with Fisher HealthCare, a part of Thermo Fisher Scientific Inc., whereby Fisher HealthCare will distribute Osmetech’s eSensor XT-8 instrument platform and molecular diagnostic tests and consumables in the US.
James White, chief executive, osmetech plc, said:
“We are delighted that Fisher HealthCare has partnered with Osmetech, highlighting the attraction of our eSensor XT-8 platform. Fisher HealthCare has a strong presence in the U.S. diagnostics market with a dedicated team of molecular sales specialists and over 150 leading edge healthcare sales representatives. We will work closely with Fisher HealthCare in order to capitalize on the significant market interest for our products and the growing number of customer leads.
“As we roll out our eSensor XT-8 platform, Fisher HealthCare’s considerable sales and marketing strength and established relationship with key customer accounts will play an important role in accelerating our market penetration”
Mark Smits, Fisher HealthCare, said:
“We are excited by the opportunity to offer our customers Osmetech’s eSensor XT-8 system. It provides next-generation multiplex testing with industry leading standards in terms of speed and ease of use and is ideally suited for the needs of the rapidly growing and decentralizing molecular diagnostics market. The value proposition of the XT-8 for diagnostic laboratories and hospitals is compelling, enabling them to meet their objectives of improving patient care and enhancing the profitability of their operations. The planned expansion of the test menu will be very attractive to our customer base”